Traditional approaches in drug discovery have primarily focused on developing inhibitors to block the function of disease-related proteins by occupying their active sites. However, around 80% of disease-related proteins within the human proteome lack distinct active sites or binding pockets, rendering them “undruggable” using conventional methods. In response to this challenge, Targeted Protein Degradation (TPD) has emerged as a revolutionary alternative approach. TPD involves the use of small molecules to induce the ubiquitination and subsequent degradation of target proteins through the cell’s natural proteasomal or lysosomal pathways. Among the leading strategies within the TPD landscape are Proteolysis-Targeting Chimeras (PROTACs) and Molecular Glue Degraders (MGDs).
PROTACs, or Proteolysis-Targeting Chimeras, are heterobifunctional compounds consisting of three key components: a ligand that binds to the protein of interest (POI), a ligand that recruits an E3 ubiquitin ligase, and a chemical linker that connects the two. The mechanism of action of PROTACs involves bringing the POI and an E3 ligase into close proximity, forming a ternary complex that facilitates the transfer of ubiquitin tags from the E2 conjugating enzyme to the POI. Once polyubiquitinated, the POI is targeted for rapid degradation by the proteasome. A notable advantage of PROTACs is their ability to induce sustained degradation of target proteins even at low concentrations of the drug.
The development of PROTACs has evolved significantly over the years. The concept was introduced in 1999, with the first small-molecule PROTAC being developed in 2008. These advancements have led to the identification of small-molecule ligands for key E3 ligases such as CRBN and VHL, which have become widely utilized in PROTAC design due to their favorable properties. Several PROTACs have progressed to clinical trials, showing promising results in various diseases including prostate cancer, breast cancer, and B-cell malignancies. However, PROTACs face challenges related to their complex structures, high molecular weight, and potential issues with cell permeability and metabolic stability, which necessitate optimization strategies.
In contrast to PROTACs, Molecular Glue Degraders (MGDs) are monovalent small molecules that induce or stabilize protein-protein interactions between an E3 ligase and a target protein, leading to ubiquitination and subsequent degradation. MGDs have shown promise in degrading a variety of target proteins and have simpler structures with lower molecular weights compared to PROTACs, making them more drug-like and potentially offering favorable pharmacokinetic profiles. Notable MGDs include thalidomide, lenalidomide, and pomalidomide, which have been approved for certain indications. However, the rational design of MGDs remains challenging due to the unpredictable nature of induced interactions and potential off-target effects.
Overall, TPD technologies like PROTACs and MGDs represent a significant advancement in drug development by enabling the complete elimination of target proteins, including previously “undruggable” ones. While these technologies hold great promise for treating various diseases, ongoing efforts are focused on improving their metabolic stability, addressing off-target effects, and diversifying the range of available E3 ligases. Computational methods and advanced analytical approaches are anticipated to enhance the identification and optimization of novel degraders, paving the way for new therapeutic possibilities in previously challenging diseases.
- TPD technologies, including PROTACs and MGDs, offer a novel approach to drug discovery by enabling the targeted degradation of disease-related proteins.
- Despite significant progress, challenges such as structural complexity and metabolic instability need to be addressed through optimization strategies.
- PROTACs have shown promise in clinical trials for various diseases, while MGDs offer simpler structures and potential advantages in pharmacokinetics.
- Ongoing research aims to expand the utility of TPD technologies by improving selectivity, efficacy, and the range of targetable proteins.
Tags: clinical trials, biotech
Read more on scientistlive.com